NO174825B - Fremgangsmåte ved påvisning av nukleotidsekvenser, nukleotidsekvens for bruk i denne og diagnostisk sett - Google Patents

Fremgangsmåte ved påvisning av nukleotidsekvenser, nukleotidsekvens for bruk i denne og diagnostisk sett Download PDF

Info

Publication number: NO174825B
Authority: NO; Norway
Prior art keywords: nucleotide; primer; diagnostic; sequence; complementary
Prior art date: 1988-03-10

Application number

NO891012A

Other languages

English (en)

Norwegian (no)

Other versions

NO174825C (ko

NO891012D0 (no

NO891012L (no

Inventor

Clive Robert Newton

Alexander Fred Markham

Original Assignee

Zeneca Ltd

Ici Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-03-10

Filing date

1989-03-09

Publication date

1994-04-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26293607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO174825(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1988-03-10 Priority claimed from GB888805692A external-priority patent/GB8805692D0/en

1988-06-15 Priority claimed from GB888814170A external-priority patent/GB8814170D0/en

1989-03-09 Application filed by Zeneca Ltd, Ici Plc filed Critical Zeneca Ltd

1989-03-09 Publication of NO891012D0 publication Critical patent/NO891012D0/no

1989-09-11 Publication of NO891012L publication Critical patent/NO891012L/no

1994-04-05 Publication of NO174825B publication Critical patent/NO174825B/no

1994-07-13 Publication of NO174825C publication Critical patent/NO174825C/no

Links

238000000034 method Methods 0.000 title claims abstract description 75
108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 39
239000002773 nucleotide Substances 0.000 claims abstract description 313
125000003729 nucleotide group Chemical group 0.000 claims abstract description 306
230000000295 complement effect Effects 0.000 claims abstract description 100
150000007523 nucleic acids Chemical class 0.000 claims abstract description 63
108020004707 nucleic acids Proteins 0.000 claims abstract description 41
102000039446 nucleic acids Human genes 0.000 claims abstract description 41
230000003321 amplification Effects 0.000 claims description 108
238000003199 nucleic acid amplification method Methods 0.000 claims description 108
239000001226 triphosphate Substances 0.000 claims description 75
235000011178 triphosphate Nutrition 0.000 claims description 75
-1 nucleoside triphosphates Chemical class 0.000 claims description 61
239000002777 nucleoside Substances 0.000 claims description 60
208000026350 Inborn Genetic disease Diseases 0.000 claims description 27
208000016361 genetic disease Diseases 0.000 claims description 26
238000001514 detection method Methods 0.000 claims description 25
230000015572 biosynthetic process Effects 0.000 claims description 22
238000003786 synthesis reaction Methods 0.000 claims description 21
239000003153 chemical reaction reagent Substances 0.000 claims description 13
239000003795 chemical substances by application Substances 0.000 claims description 10
230000000379 polymerizing effect Effects 0.000 claims description 10
125000003835 nucleoside group Chemical group 0.000 claims description 7
238000006116 polymerization reaction Methods 0.000 claims description 4
238000009007 Diagnostic Kit Methods 0.000 claims description 2
238000012545 processing Methods 0.000 claims description 2
238000010306 acid treatment Methods 0.000 claims 1
239000002243 precursor Substances 0.000 claims 1
238000002405 diagnostic procedure Methods 0.000 abstract 1
239000013615 primer Substances 0.000 description 333
239000000047 product Substances 0.000 description 138
108020004414 DNA Proteins 0.000 description 91
239000000523 sample Substances 0.000 description 87
108091034117 Oligonucleotide Proteins 0.000 description 52
230000035772 mutation Effects 0.000 description 43
238000003752 polymerase chain reaction Methods 0.000 description 42
102000004190 Enzymes Human genes 0.000 description 30
108090000790 Enzymes Proteins 0.000 description 30
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 28
239000000499 gel Substances 0.000 description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
238000006243 chemical reaction Methods 0.000 description 16
239000013612 plasmid Substances 0.000 description 16
101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 15
238000001962 electrophoresis Methods 0.000 description 14
239000002753 trypsin inhibitor Substances 0.000 description 14
201000010099 disease Diseases 0.000 description 13
239000011541 reaction mixture Substances 0.000 description 13
238000012800 visualization Methods 0.000 description 13
239000000872 buffer Substances 0.000 description 12
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
108700028369 Alleles Proteins 0.000 description 10
238000010438 heat treatment Methods 0.000 description 10
238000009396 hybridization Methods 0.000 description 10
239000012985 polymerization agent Substances 0.000 description 10
238000001816 cooling Methods 0.000 description 9
108010006785 Taq Polymerase Proteins 0.000 description 8
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
102000051631 human SERPINA1 Human genes 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
238000012360 testing method Methods 0.000 description 8
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 8
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 8
108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 7
239000003550 marker Substances 0.000 description 7
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 7
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
230000008859 change Effects 0.000 description 6
229940104302 cytosine Drugs 0.000 description 6
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
239000011543 agarose gel Substances 0.000 description 5
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 5
229960005542 ethidium bromide Drugs 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000002987 primer (paints) Substances 0.000 description 5
230000002787 reinforcement Effects 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 5
229930024421 Adenine Natural products 0.000 description 4
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
101710081722 Antitrypsin Proteins 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
208000002903 Thalassemia Diseases 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
229960000643 adenine Drugs 0.000 description 4
238000009835 boiling Methods 0.000 description 4
238000013461 design Methods 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
239000012160 loading buffer Substances 0.000 description 4
238000002156 mixing Methods 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
229940113082 thymine Drugs 0.000 description 4
241001515965 unidentified phage Species 0.000 description 4
229940035893 uracil Drugs 0.000 description 4
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 3
108010017826 DNA Polymerase I Proteins 0.000 description 3
102000004594 DNA Polymerase I Human genes 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
230000001687 destabilization Effects 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
239000000975 dye Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
230000006872 improvement Effects 0.000 description 3
229910001629 magnesium chloride Inorganic materials 0.000 description 3
239000000203 mixture Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 2
229960005508 8-azaguanine Drugs 0.000 description 2
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
206010069754 Acquired gene mutation Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
239000003155 DNA primer Substances 0.000 description 2
102100031780 Endonuclease Human genes 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
229920001917 Ficoll Polymers 0.000 description 2
XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 description 2
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
241000589500 Thermus aquaticus Species 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
238000000246 agarose gel electrophoresis Methods 0.000 description 2
229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
229910052921 ammonium sulfate Inorganic materials 0.000 description 2
235000011130 ammonium sulphate Nutrition 0.000 description 2
230000001475 anti-trypsic effect Effects 0.000 description 2
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000000368 destabilizing effect Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
239000012502 diagnostic product Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000001976 enzyme digestion Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
229940029575 guanosine Drugs 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
229940059904 light mineral oil Drugs 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
230000010355 oscillation Effects 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000037439 somatic mutation Effects 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
238000012549 training Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
101100025420 Arabidopsis thaliana XI-C gene Proteins 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 description 1
102100026735 Coagulation factor VIII Human genes 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
208000027219 Deficiency disease Diseases 0.000 description 1
206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
201000003542 Factor VIII deficiency Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000034502 Haemoglobin C disease Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
108010066717 Q beta Replicase Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000008051 TBE buffer Substances 0.000 description 1
241000589596 Thermus Species 0.000 description 1
PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
201000006288 alpha thalassemia Diseases 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
238000000137 annealing Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000004252 chorionic villi Anatomy 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000007334 copolymerization reaction Methods 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000005549 deoxyribonucleoside Substances 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
238000011161 development Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
MKZUDFZKTZOCRS-UHFFFAOYSA-N diphosphono hydrogen phosphate;1h-pyrimidine-2,4-dione Chemical compound O=C1C=CNC(=O)N1.OP(O)(=O)OP(O)(=O)OP(O)(O)=O MKZUDFZKTZOCRS-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
102000054766 genetic haplotypes Human genes 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
238000009830 intercalation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000011068 loading method Methods 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000011325 microbead Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
244000052769 pathogen Species 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000037452 priming Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
108700042226 ras Genes Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
229950010342 uridine triphosphate Drugs 0.000 description 1
PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 1
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000004876 x-ray fluorescence Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Analytical Chemistry (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Immunology (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pathology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Nonwoven Fabrics (AREA)
Communication Cables (AREA)
Suspension Of Electric Lines Or Cables (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO891012A 1988-03-10 1989-03-09 Fremgangsmåte ved påvisning av nukleotidsekvenser, nukleotidsekvens for bruk i denne og diagnostisk sett NO174825B (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB888805692A GB8805692D0 (en)	1988-03-10	1988-03-10	Method of detecting nucleotide sequences
GB888814170A GB8814170D0 (en)	1988-06-15	1988-06-15	Method of detecting nucleotide sequences

Publications (4)

Publication Number	Publication Date
NO891012D0 NO891012D0 (no)	1989-03-09
NO891012L NO891012L (no)	1989-09-11
NO174825B true NO174825B (no)	1994-04-05
NO174825C NO174825C (ko)	1994-07-13

Family

ID=26293607

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO891012A NO174825B (no)	1988-03-10	1989-03-09	Fremgangsmåte ved påvisning av nukleotidsekvenser, nukleotidsekvens for bruk i denne og diagnostisk sett

Country Status (26)

Country	Link
US (1)	US5595890A (ko)
EP (1)	EP0332435B2 (ko)
JP (1)	JP2853864B2 (ko)
KR (1)	KR970003151B1 (ko)
CN (1)	CN1034673C (ko)
AT (1)	ATE75262T1 (ko)
AU (1)	AU614584B2 (ko)
BG (1)	BG87585A (ko)
BR (1)	BR8901136A (ko)
CA (1)	CA1323592C (ko)
DE (1)	DE68901285D1 (ko)
DK (1)	DK175527B1 (ko)
ES (1)	ES2039294T5 (ko)
FI (1)	FI891126A (ko)
GR (2)	GR3004442T3 (ko)
HU (1)	HUT52565A (ko)
IE (1)	IE61148B1 (ko)
IL (1)	IL89545A (ko)
MY (1)	MY104957A (ko)
NO (1)	NO174825B (ko)
NZ (1)	NZ228266A (ko)
PL (1)	PL162338B1 (ko)
PT (1)	PT89980B (ko)
TN (1)	TNSN89026A1 (ko)
YU (1)	YU49789A (ko)
ZW (1)	ZW3388A1 (ko)

Families Citing this family (260)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4038804A1 (de) *	1990-10-09	1992-04-16	Boehringer Mannheim Gmbh	Verfahren zur genus- oder/und spezies-spezifischen detektion von bakterien in einer probenfluessigkeit
ATE108491T1 (de) *	1988-03-18	1994-07-15	Baylor College Medicine	Mutationsnachweis durch kompetitiven oligonukleotid-priming.
FR2650840B1 (fr) *	1989-08-11	1991-11-29	Bertin & Cie	Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
GB8920097D0 (en) *	1989-09-06	1989-10-18	Ici Plc	Amplification processes
JPH03123500A (ja) *	1989-10-06	1991-05-27	Canon Inc	核酸の分別方法
GB9001181D0 (en) *	1990-01-18	1990-03-21	Imp Cancer Res Tech	Genetic assay
IL97222A (en) *	1990-02-16	1995-08-31	Orion Yhtymae Oy	Method and Responder for Determining Special Changes to Nucleotide
US6013431A (en) *	1990-02-16	2000-01-11	Molecular Tool, Inc.	Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
GB9006924D0 (en) *	1990-03-28	1990-05-23	Imperial College	Prognosis of hepatitis infection
DE69126064T2 (de) *	1990-06-22	1997-08-28	Hoffmann La Roche	Nachweis von schwachen Metabolisierungsreagentien von Drogen
US5844108A (en) *	1990-06-22	1998-12-01	Roche Molecular Systems, Inc.	Primers targeted to NAT2 gene for detection of poor metabolizers of drugs
GB9019512D0 (en) *	1990-09-06	1990-10-24	Ici Plc	Assay method
FR2668162B1 (fr) *	1990-10-17	1993-01-22	Eurobio Lab	Fragments d'adn, procede et coffret de diagnostic pour la detection des porteurs de la mutation delta-f-508 responsable de la mucoviscidose.
IE66125B1 (en) *	1991-01-31	1995-12-13	Zeneca Ltd	Detection method for variant nucleotides
US6004744A (en)	1991-03-05	1999-12-21	Molecular Tool, Inc.	Method for determining nucleotide identity through extension of immobilized primer
NZ244089A (en) *	1991-08-27	1995-01-27	Zeneca Ltd	Characterising genomic dna samples into individual sample codes using amplification and type specific primers to form a database of individual sample codes
US5853989A (en) *	1991-08-27	1998-12-29	Zeneca Limited	Method of characterisation of genomic DNA
DE4129653A1 (de) *	1991-09-06	1993-03-11	Boehringer Mannheim Gmbh	Verfahren zum nachweis aehnlicher nukleinsaeuren
IL103935A0 (en) *	1991-12-04	1993-05-13	Du Pont	Method for the identification of microorganisms by the utilization of directed and arbitrary dna amplification
US5541060A (en) *	1992-04-22	1996-07-30	Arch Development Corporation	Detection of glucokinase-linked early-onset non-insulin-dependent diabetes mellitus
US6207368B1 (en)	1992-08-04	2001-03-27	Beckman Coulter, Inc.	Methods and reagents for controlling chain extension and ligation chain reactions
US6180338B1 (en)	1992-08-04	2001-01-30	Beckman Coulter, Inc.	Method, reagent and kit for the detection and amplification of nucleic acid sequences
WO1994008047A1 (en) *	1992-09-25	1994-04-14	Abbott Laboratories	Ligase chain reaction method for detecting small mutations
US6335184B1 (en)	1993-07-23	2002-01-01	Bio-Rad Laboratories, Inc.	Linked linear amplification of nucleic acids
JPH09500539A (ja) *	1993-07-23	1997-01-21	バイオ−ラッド・ラボラトリーズ・インコーポレーテッド	核酸のリンクされた線形増幅
AU1911395A (en) *	1994-02-04	1995-08-21	Beckman Instruments, Inc.	Method, reagent and kit for the detection and amplification of nucleic acid sequences
AU686004B2 (en)	1994-08-12	1998-01-29	Myriad Genetics, Inc.	In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
ATE198623T1 (de)	1994-08-12	2001-01-15	Myriad Genetics Inc	Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs
FR2737732B1 (fr) *	1995-08-07	1997-10-10	Ass Francaise Contre La Myopat	Test co-dominant de diagnostic genetique
US5837492A (en)	1995-12-18	1998-11-17	Myriad Genetics, Inc.	Chromosome 13-linked breast cancer susceptibility gene
ATE230759T1 (de)	1995-12-18	2003-01-15	Myriad Genetics Inc	Chromosom 13 verbundene brustkrebsempfindlichkeitsgen brca2
ATE352629T1 (de)	1995-12-22	2007-02-15	Univ Utah Res Found	Kvlqt1 - ein gen des long-qt-syndroms, welches für kvlqt1 kodiert und welches sich mit mink zusammensetzt, um iks-kaliumkanäle des herzens zu bilden
NO960163D0 (no) *	1996-01-15	1996-01-15	Thomas Berg	Mutasjonsdeteksjon av bovin
US5612473A (en) *	1996-01-16	1997-03-18	Gull Laboratories	Methods, kits and solutions for preparing sample material for nucleic acid amplification
WO1997035033A1 (en)	1996-03-19	1997-09-25	Molecular Tool, Inc.	Method for determining the nucleotide sequence of a polynucleotide
GB9609441D0 (en) *	1996-05-04	1996-07-10	Zeneca Ltd	Process
US6361940B1 (en)	1996-09-24	2002-03-26	Qiagen Genomics, Inc.	Compositions and methods for enhancing hybridization and priming specificity
IL119342A0 (en) *	1996-10-02	1997-01-10	Yeda Research And Development C	Methods for priming and DNA sequencing
US5888778A (en) *	1997-06-16	1999-03-30	Exact Laboratories, Inc.	High-throughput screening method for identification of genetic mutations or disease-causing microorganisms using segmented primers
US6566101B1 (en)	1997-06-16	2003-05-20	Anthony P. Shuber	Primer extension methods for detecting nucleic acids
GB9721240D0 (en) *	1997-10-08	1997-12-03	Zeneca Ltd	Assay
US6794133B1 (en)	1997-12-11	2004-09-21	The General Hospital Corporation	Broad range PCR amplification techniques
WO1999044045A1 (en) *	1998-02-27	1999-09-02	Massachusetts Institute Of Technology	Single molecule detection with surface-enhanced raman scattering and applications in dna or rna sequencing
GB9812768D0 (en) *	1998-06-13	1998-08-12	Zeneca Ltd	Methods
US6207379B1 (en)	1998-09-11	2001-03-27	One Lambda	Method for amplification of DNA
CN1333831A (zh)	1998-12-08	2002-01-30	儿童医院及地区医疗中心	区分大肠杆菌0157∶h7和其它菌株的多态性位点
US6503718B2 (en)	1999-01-10	2003-01-07	Exact Sciences Corporation	Methods for detecting mutations using primer extension for detecting disease
US6280947B1 (en)	1999-08-11	2001-08-28	Exact Sciences Corporation	Methods for detecting nucleotide insertion or deletion using primer extension
IL145417A0 (en)	1999-03-18	2002-06-30	Exiqon As	Detection of mutations in genes by specific lna primers
US20060275782A1 (en) *	1999-04-20	2006-12-07	Illumina, Inc.	Detection of nucleic acid reactions on bead arrays
US20030207295A1 (en) *	1999-04-20	2003-11-06	Kevin Gunderson	Detection of nucleic acid reactions on bead arrays
US20020025519A1 (en) *	1999-06-17	2002-02-28	David J. Wright	Methods and oligonucleotides for detecting nucleic acid sequence variations
US20030165913A1 (en) *	1999-06-17	2003-09-04	Sha-Sha Wang	Methods for detecting nucleic acid sequence variations
EP1061134A3 (en) *	1999-06-17	2003-01-08	Becton Dickinson and Company	Oligonucleotides for amplification and detection of hemochromatosis genes
WO2000079009A2 (en)	1999-06-22	2000-12-28	Invitrogen Corporation	Improved primers and methods for the detection and discrimination of nucleic acids
US6830902B1 (en)	1999-07-02	2004-12-14	Invitrogen Corporation	Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
EP1072679A3 (en) *	1999-07-20	2002-07-31	Agilent Technologies, Inc. (a Delaware corporation)	Method of producing nucleic acid molecules with reduced secondary structure
DE10038229B4 (de)	1999-08-24	2011-06-09	LG Electronics Inc., Kangnam-gu	Verfahren und Vorrichtung zur Ratenanpassung in einem Mobilkommunikationssystem
US6528066B1 (en) *	1999-09-14	2003-03-04	University Of Iowa Research Foundation	Variant varicella-zoster viruses and methods of use
WO2001023410A2 (en) *	1999-09-28	2001-04-05	Genaissance Pharmaceuticals, Inc.	Drug target isogenes: polymorphisms in the interleukin 13 gene
US20030148301A1 (en) *	1999-12-10	2003-08-07	Toshiya Aono	Method of detecting nucleotide polymorphism
AU2001236491A1 (en) *	2000-01-18	2003-09-16	Quantom Dot Corporation	Oligonucleotide-tagged semiconductor nanocrystals for microarray and fluorescence in situ hybridization
US7582420B2 (en)	2001-07-12	2009-09-01	Illumina, Inc.	Multiplex nucleic acid reactions
US7955794B2 (en) *	2000-09-21	2011-06-07	Illumina, Inc.	Multiplex nucleic acid reactions
US20050214825A1 (en) *	2000-02-07	2005-09-29	John Stuelpnagel	Multiplex sample analysis on universal arrays
US8076063B2 (en) *	2000-02-07	2011-12-13	Illumina, Inc.	Multiplexed methylation detection methods
US7435541B2 (en) *	2000-05-23	2008-10-14	Sequenom, Inc.	Restriction enzyme genotyping
US7659054B1 (en) *	2000-05-23	2010-02-09	Nuvelo, Inc.	Methods for genetic analysis of DNA to detect sequence variances
AU2000257122A1 (en) *	2000-07-12	2002-01-21	Bionex, Inc.	Method for detecting sequence variation of nucleic acid
JP3638516B2 (ja) *	2000-09-28	2005-04-13	株式会社日立製作所	核酸検出方法および核酸検出キット
US6428964B1 (en)	2001-03-15	2002-08-06	Exact Sciences Corporation	Method for alteration detection
CA2440146A1 (en) *	2001-03-30	2002-10-24	Amersham Biosciences Ab	P450 single nucleotide polymorphism biochip analysis
CN1186456C (zh) *	2001-04-30	2005-01-26	曹卫	通用模板核酸检测方法和试剂盒
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7888324B2 (en)	2001-08-01	2011-02-15	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
WO2003027309A2 (en)	2001-09-24	2003-04-03	One Lambda	Diagnostic probe detection system
US20030165859A1 (en) *	2001-10-23	2003-09-04	Invitrogen Corporation	Primers and methods for the detection and discrimination of nucleic acids
AU2003206869A1 (en) *	2002-02-08	2003-09-02	Evotec Technologies Gmbh	Specific multiplex analysis of nucleic acids
AU2003213107A1 (en)	2002-02-15	2003-09-09	Exact Sciences Corporation	Methods for analysis of molecular events
JP3752466B2 (ja) *	2002-04-24	2006-03-08	株式会社日立製作所	遺伝子検査方法
JP2006517385A (ja)	2002-08-02	2006-07-27	オーキッドセルマークインコーポレイテッド	遺伝子型特定のための方法および組成物
US7192700B2 (en)	2002-12-20	2007-03-20	Orchid Cellmark Inc.	Methods and compositions for conducting primer extension and polymorphism detection reactions
US9394332B2 (en)	2002-08-29	2016-07-19	Epigenomics Ag	Method for bisulfite treatment
US20040121374A1 (en) *	2002-10-02	2004-06-24	Yoshihide Iwaki	Method for detecting single nucleotide polymorphisms
US20040259105A1 (en) *	2002-10-03	2004-12-23	Jian-Bing Fan	Multiplex nucleic acid analysis using archived or fixed samples
ATE399882T1 (de) *	2002-11-07	2008-07-15	Yoichi Matsubara	Verfahren zum genmutationsnachweis
US7511131B2 (en)	2002-11-13	2009-03-31	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
CN1774511B (zh)	2002-11-27	2013-08-21	斯昆诺有限公司	用于序列变异检测和发现的基于断裂的方法和系统
JP2006516391A (ja) *	2003-01-29	2006-07-06	エフ．ホフマン−ラ　ロシュ　アーゲー	重亜硫酸塩処理の改良された方法
CA2518452A1 (en) *	2003-03-11	2004-09-23	Gene Check, Inc.	Reca-assisted allele specific oligonucleotide extension method for detecting mutations, snps and specific sequences
EP1611254B1 (en)	2003-03-31	2014-09-10	Roche Diagnostics GmbH	Compositions and methods for detecting certain flaviviruses, including members of the japanese encephalitis virus serogroup
US20040219532A1 (en) *	2003-04-30	2004-11-04	Sampson Jeffrey R.	Internal references measurements
US9045796B2 (en)	2003-06-20	2015-06-02	Illumina, Inc.	Methods and compositions for whole genome amplification and genotyping
US20040259100A1 (en) *	2003-06-20	2004-12-23	Illumina, Inc.	Methods and compositions for whole genome amplification and genotyping
US20050181394A1 (en) *	2003-06-20	2005-08-18	Illumina, Inc.	Methods and compositions for whole genome amplification and genotyping
GB0317592D0 (en)	2003-07-26	2003-08-27	Astrazeneca Ab	Method
EP2982240B1 (en) *	2003-08-29	2019-07-31	Instituto Nacional de Tecnologia Agropecuaria	Rice plants having increased tolerance to imidazolinone herbicides
US9394565B2 (en)	2003-09-05	2016-07-19	Agena Bioscience, Inc.	Allele-specific sequence variation analysis
WO2005054502A1 (en)	2003-12-02	2005-06-16	Roche Diagnostics Gmbh	Improved method for bisulfite treatment
US7129049B2 (en)	2003-12-22	2006-10-31	Regents Of The University Of Minnesota	Method of detecting equine glycogen storage disease IV
US7432082B2 (en) *	2004-03-22	2008-10-07	Basf Ag	Methods and compositions for analyzing AHASL genes
CA2561381C (en)	2004-03-26	2015-05-12	Sequenom, Inc.	Base specific cleavage of methylation-specific amplification products in combination with mass analysis
US20050287558A1 (en)	2004-05-05	2005-12-29	Crooke Rosanne M	SNPs of apolipoprotein B and modulation of their expression
US7939251B2 (en)	2004-05-06	2011-05-10	Roche Molecular Systems, Inc.	SENP1 as a marker for cancer
EP2592155B2 (en)	2004-06-04	2019-09-11	Genentech, Inc.	EGFR mutations
WO2006005081A2 (en) *	2004-06-30	2006-01-12	Applera Corporation	Compositions and methods for identifying nucleotides in polynucleotide sequences
UA97344C2 (uk) *	2004-07-30	2012-02-10	Басф Агрокемікел Продактс Б.В.	Резистентні до імідазолінонових гербіцидів рослини соняшнику , полінуклеотиди, що кодують резистентні до гербіцидів великі субодиниці білків ацетогідроксикислотної синтази
WO2006026654A2 (en)	2004-08-27	2006-03-09	Exact Sciences Corporation	Method for detecting a recombinant event
EP1632578A1 (en) *	2004-09-03	2006-03-08	Roche Diagnostics GmbH	DNA decontamination method
US9109256B2 (en)	2004-10-27	2015-08-18	Esoterix Genetic Laboratories, Llc	Method for monitoring disease progression or recurrence
JP2006129811A (ja) *	2004-11-08	2006-05-25	Hitachi Ltd	試料核酸の分析方法、分析装置および分析キット
US20060275792A1 (en) *	2004-11-15	2006-12-07	Lee Jun E	Enhancement of nucleic acid amplification using double-stranded DNA binding proteins
US20060105348A1 (en) *	2004-11-15	2006-05-18	Lee Jun E	Compositions and methods for the detection and discrimination of nucleic acids
GB0428255D0 (en)	2004-12-23	2005-01-26	Health Prot Agency	Detection of nucleic acid mutations
EP3581024A1 (en) *	2005-03-02	2019-12-18	Instituto Nacional de Tecnologia Agropecuaria	Herbicide-resistant rice plants, polynucleotides encoding herbicide-resistant acetohydroxyacid synthase large subunit proteins, and methods of use
GB2424886A (en)	2005-04-04	2006-10-11	Dxs Ltd	Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations
WO2006112737A1 (en)	2005-04-20	2006-10-26	Protemix Discovery Limited	Vesiculins
WO2007044071A2 (en)	2005-04-21	2007-04-19	Exact Sciences Corporation	Analysis of heterogeneous nucleic acid samples
EA020462B1 (ru) *	2005-07-01	2014-11-28	Басф Се	Резистентные к гербицидам растения подсолнечника, полинуклеотиды, кодирующие резистентные к гербицидам большие субъединицы белков ацетогидроксикислотной синтазы, и применение растений и полинуклеотидов
GB0514913D0 (en) *	2005-07-20	2005-08-24	Univ Birmingham	Polymorphism
US11111544B2 (en)	2005-07-29	2021-09-07	Natera, Inc.	System and method for cleaning noisy genetic data and determining chromosome copy number
WO2007134014A2 (en)	2006-05-05	2007-11-22	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating expression of gcgr
US7759062B2 (en)	2006-06-09	2010-07-20	Third Wave Technologies, Inc.	T-structure invasive cleavage assays, consistent nucleic acid dispensing, and low level target nucleic acid detection
KR100812259B1 (ko) *	2006-06-12	2008-03-10	주식회사 씨젠	기지의 서열에 인접한 미지의 ｄｎａ 서열을 증폭하는 방법
CA2655497A1 (en)	2006-06-23	2007-12-27	Myriad Genetics, Inc.	Dpyd gene variants and use thereof
BRPI0716555A2 (pt)	2006-09-07	2013-09-24	Astrazeneca Ab	mÉtodos para prever a probabilidade de que um paciente É um candidato para tratamento com uma droga de ret responderÁ ao citado tratamento, e para tratar um paciente, iniciador direto mutante de arms, e, kit diagnàstico
EP2069497B1 (en) *	2006-11-02	2013-08-14	University of Utah Research Foundation	Oligonucleotides for use in allele-specific pcr
UA108733C2 (uk)	2006-12-12	2015-06-10		Толерантна до гербіциду рослина соняшника
US9938641B2 (en) *	2006-12-18	2018-04-10	Fluidigm Corporation	Selection of aptamers based on geometry
EP2097448A4 (en)	2006-12-22	2010-07-21	Univ Utah Res Found	METHOD FOR DETECTING DISEASES AND OCULAR DISEASE CONDITIONS AND TREATMENT THEREOF
US8314220B2 (en) *	2007-01-26	2012-11-20	Agilent Technologies, Inc.	Methods compositions, and kits for detection of microRNA
CA2682082A1 (en)	2007-03-24	2008-10-02	Genzyme Corporation	Administering antisense oligonucleotides complementary to human apolipoprotein b
US10017827B2 (en)	2007-04-04	2018-07-10	Nidera S.A.	Herbicide-resistant sunflower plants with multiple herbicide resistant alleles of AHASL1 and methods of use
AU2008239594B2 (en)	2007-04-13	2013-10-24	Beth Israel Deaconess Medical Center	Methods for treating cancer resistant to ErbB therapeutics
CN105112503B (zh)	2007-05-03	2018-10-16	一兰姆达公司	使用微粒和独特探针组筛选结合相互作用的方法
CN108753946A (zh)	2007-05-21	2018-11-06	健泰科生物技术公司	用于鉴定和治疗狼疮的方法和组合物
US20100203051A1 (en)	2007-05-31	2010-08-12	The University Of Queensland	Diagnostic markers for ankylosing spondylitis and uses thereof
WO2008153804A2 (en) *	2007-05-31	2008-12-18	Monsanto Technology Llc	Soybean polymorphisms and methods of genotyping
CA2694832A1 (en)	2007-08-06	2009-02-12	Orion Genomics Llc	Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the igf2 gene
CN101821409B (zh)	2007-08-29	2014-08-27	孟山都技术公司	用于优选性状育种的方法和组合物
CA2639416C (en)	2007-09-11	2019-12-31	F. Hoffmann-La Roche Ag	Diagnostic test for susceptibility to b-raf kinase inhibitors
GB2453173A (en)	2007-09-28	2009-04-01	Dxs Ltd	Polynucleotide primers
US20100324154A1 (en)	2007-11-01	2010-12-23	Hageman Gregory S	Assessing susceptibility to vascular disorders
CA2704487A1 (en) *	2007-11-02	2009-06-18	Luminex Molecular Diagnostics, Inc.	One-step target detection assay
WO2009059199A2 (en) *	2007-11-02	2009-05-07	Hunch Inc.	Interactive machine learning advice facility
JP5188789B2 (ja) *	2007-11-29	2013-04-24	株式会社日立製作所	核酸の定量方法
JP5530185B2 (ja)	2008-02-05	2014-06-25	オリンパス株式会社	核酸検出方法及び核酸検出用キット
BRPI0911551B8 (pt)	2008-04-24	2023-10-03	Monsanto Technology Llc	Método para produzir planta de soja resistente a ferrugem asiática da soja (asr)
EP2113574A1 (en)	2008-04-28	2009-11-04	Biotype AG	Substances and methods for a DNA based profiling assay
US8911948B2 (en) *	2008-04-30	2014-12-16	Integrated Dna Technologies, Inc.	RNase H-based assays utilizing modified RNA monomers
JP5539325B2 (ja)	2008-04-30	2014-07-02	インテグレイテツド・デイー・エヌ・エイ・テクノロジーズ・インコーポレイテツド	修飾されたｒｎａ単量体を用いるｒｎアーゼｈを基礎とするアッセイ
US9115391B2 (en)	2008-07-02	2015-08-25	Arkray, Inc.	Method of detecting a polymorphism at a polymorphism site
JP5590781B2 (ja)	2008-07-10	2014-09-17	オリンパス株式会社	標的核酸比率推定方法
CN102186996A (zh) *	2008-10-20	2011-09-14	霍夫曼-拉罗奇有限公司	改进的等位基因特异性扩增
EP2186907A1 (en)	2008-11-11	2010-05-19	Deutsches Primatenzentrum GmbH	X-chromosomal variation as a diagnostic and therapeutic marker for the progression to AIDS
EP2396661A4 (en)	2009-02-11	2013-10-30	Caris Mpi Inc	MOLECULAR PROFILING OF TUMORS
EP2396429B1 (en)	2009-02-11	2015-05-27	Orion Genomics, LLC	Combinations of polymorphisms for determining allele-specific expression of igf2
JP5457222B2 (ja) *	2009-02-25	2014-04-02	エフ．ホフマン−ラロシュアーゲー	小型化ハイスループット核酸分析
US9347092B2 (en) *	2009-02-25	2016-05-24	Roche Molecular System, Inc.	Solid support for high-throughput nucleic acid analysis
WO2010107838A1 (en)	2009-03-16	2010-09-23	Isis Pharmaceuticals, Inc.	Targeting apolipoprotein b for the reduction of apolipoprotein c-iii
ES2932874T3 (es)	2009-03-25	2023-01-27	Genentech Inc	Anticuerpos anti-FGFR3 y métodos que utilizan los mismos
WO2010112033A2 (en)	2009-03-31	2010-10-07	Østjysk Innovation A/S	Method for estimating the risk of having or developing multiple sclerosis using sequence polymorphisms in a specific region of chromosome x
US20100299773A1 (en) *	2009-05-20	2010-11-25	Monsanto Technology Llc	Methods and compositions for selecting an improved plant
CA2766351C (en)	2009-06-29	2018-02-27	Luminex Corporation	Chimeric primers with hairpin conformations and methods of using same
KR101953075B1 (ko)	2009-10-07	2019-02-27	제넨테크, 인크.	루푸스의 치료, 진단 및 모니터링 방법
WO2011056687A2 (en)	2009-10-27	2011-05-12	Swift Biosciences, Inc.	Polynucleotide primers and probes
CA2779223A1 (en)	2009-10-27	2011-05-12	Caris Mpi, Inc.	Molecular profiling for personalized medicine
US8614071B2 (en)	2009-12-11	2013-12-24	Roche Molecular Systems, Inc.	Preferential amplification of mRNA over DNA using chemically modified primers
US9238832B2 (en)	2009-12-11	2016-01-19	Roche Molecular Systems, Inc.	Allele-specific amplification of nucleic acids
EP2450443B1 (en)	2010-01-21	2016-05-11	ARKRAY, Inc.	Target sequence amplification method, polymorphism detection method, and reagents for use in the methods
WO2011128096A1 (en)	2010-04-16	2011-10-20	Roche Diagnostics Gmbh	Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
US9340833B2 (en)	2010-04-30	2016-05-17	Arkray, Inc.	Method for adjusting amplification efficiency of target polynucleotide
JP5830268B2 (ja) *	2010-04-30	2015-12-09	アークレイ株式会社	標的ポリヌクレオチドの増幅効率の調節方法
GB201008125D0 (en)	2010-05-14	2010-06-30	Biofortuna Ltd	Tissue typing assays and kits
US11939634B2 (en)	2010-05-18	2024-03-26	Natera, Inc.	Methods for simultaneous amplification of target loci
US20190010543A1 (en)	2010-05-18	2019-01-10	Natera, Inc.	Methods for simultaneous amplification of target loci
US9982304B2 (en)	2010-09-03	2018-05-29	The Johns Hopkins University	ARID1A and PPP2R1A mutations in cancer
WO2012052758A1 (en)	2010-10-22	2012-04-26	Astrazeneca Ab	Response biomarkers for iap antagonists in human cancers
GB2506760B (en)	2011-01-14	2015-07-22	Genefirst Ltd	Allele specific primers for EGFR exon 21 specific mutations
GB201101200D0 (en)	2011-01-24	2011-03-09	King S College	Method
BR112013020220B1 (pt)	2011-02-09	2020-03-17	Natera, Inc.	Método para determinar o estado de ploidia de um cromossomo em um feto em gestação
WO2012135053A2 (en)	2011-03-25	2012-10-04	Integrated Dna Technologies, Inc.	Rnase h-based assays utilizing modified rna monomers
BR112013025356B1 (pt)	2011-04-01	2022-11-16	Genentech, Inc	Método in vitro de predição da sensibilidade do crescimento de uma célula tumoral para um inibidor de akt1
US10172305B2 (en)	2011-04-29	2019-01-08	Monsanto Technology Llc	Diagnostic molecular markers for seed lot purity traits in soybeans
EP3560329A1 (en)	2011-05-02	2019-10-30	Board of Regents of the University of Nebraska	Plants with useful traits and related methods
SG2014008585A (en)	2011-08-31	2014-04-28	Hoffmann La Roche	Method for predicting risk of hypertension associated with anti-angiogenesis therapy
PT3517615T (pt)	2011-08-31	2022-08-09	Seminis Vegetable Seeds Inc	Métodos e composições para a firmeza da melancia
JP2014526900A (ja)	2011-08-31	2014-10-09	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	血管新生阻害剤に対する応答性
MX2014002990A (es)	2011-09-19	2014-05-21	Genentech Inc	Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
KR20140082796A (ko)	2011-10-14	2014-07-02	제넨테크, 인크.	항-HtrA1 항체 및 사용 방법
BR112014011127A2 (pt)	2011-11-10	2017-05-16	Genentech Inc	métodos para tratar, diagnosticar e monitorar doença de alzheimer
AU2012342682A1 (en)	2011-11-23	2014-05-22	F. Hoffmann-La Roche Ag	Responsiveness to angiogenesis inhibitors
MX2014006529A (es)	2011-11-30	2014-11-25	Genentech Inc	Mutaciones de erbb3 en cancer.
JP2015501652A (ja)	2011-12-14	2015-01-19	アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａＡｋｔｉｅｂｏｌａｇ	Ｇａｂｒ−ａ２診断
EP2607495A1 (en)	2011-12-23	2013-06-26	Genomica S.A.U.	Method for detection of KRAS mutations
US10633707B2 (en)	2012-04-10	2020-04-28	Vib Vzw	Markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the DNA base excision repair pathway
US10294529B2 (en)	2012-04-10	2019-05-21	Life Sciences Research Partners Vzw	Microsatellite instability markers in detection of cancer
EP3741871A3 (en)	2012-04-19	2021-02-17	The Medical College of Wisconsin, Inc.	Highly sensitive surveillance using detection of cell free dna
US10077474B2 (en)	2012-05-29	2018-09-18	Abbott Molecular, Inc.	Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
US20140100126A1 (en)	2012-08-17	2014-04-10	Natera, Inc.	Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
EP2711432A1 (en)	2012-09-21	2014-03-26	Genomica S.A.U.	Method for detection of BRAF and PI3K mutations
US10314253B2 (en)	2012-12-04	2019-06-11	Seminis Vegetable Seeds, Inc.	Methods and compositions for watermelon sex expression
KR102182488B1 (ko)	2013-02-25	2020-11-24	제넨테크, 인크.	약물 내성 akt 돌연변이체의 검출 및 치료를 위한 방법 및 조성물
US10294489B2 (en)	2013-03-15	2019-05-21	Board Of Trustees Of Southern Illinois University	Soybean resistant to cyst nematodes
US20140272956A1 (en)	2013-03-15	2014-09-18	Abbott Molecular Inc.	Method for amplification and assay of rna fusion gene variants, method of distinguishing same and related primers, probes, and kits
WO2014149356A1 (en)	2013-03-15	2014-09-25	Abbott Molecular Inc.	Detection of bisulfite converted nucleotide sequences
CN105074009B (zh)	2013-03-19	2017-09-26	凸版印刷株式会社	Egfr抑制剂的敏感性的预测方法
US10059999B2 (en)	2013-06-10	2018-08-28	Monsanto Technology Llc	Molecular markers associated with soybean tolerance to low iron growth conditions
US10767188B2 (en)	2013-09-25	2020-09-08	Nutech Ventures	Methods and compositions for obtaining useful plant traits
NZ630628A (en)	2013-10-08	2015-04-24	Seminis Vegetable Seeds Inc	Methods and compositions for peronospora resistance in spinach
JP2015096049A (ja)	2013-11-15	2015-05-21	凸版印刷株式会社	Ｖｅｇｆ阻害剤長期奏功性予測方法
NZ630717A (en)	2013-11-27	2016-04-29	Seminis Vegetable Seeds Inc	Disease resistance loci in onion
EP3632202B1 (en)	2014-02-21	2022-07-20	Syngenta Participations Ag	Genetic loci associated with increased fertility in maize
NZ630710A (en)	2014-02-27	2016-03-31	Seminis Vegetable Seeds Inc	Compositions and methods for peronospora resistance in spinach
BR112016022620A2 (pt)	2014-03-31	2017-10-10	Debiopharm Int Sa	cdna que codifica um polipeptídeo de fusão, vetor, célula procariotica ou eucariotica, sequência polinucleotídica, polipeptídeo de fusão, anticorpo ou fragmento de ligação, par de primers, sonda oligonucleotídica, oligonucleotídeo, sirna dirigido a um rna mensageiro, inibidor da atividade quinase fgfr, método de terapia e método para identificar um composto
TW201620526A (zh) *	2014-06-17	2016-06-16	愛羅海德研究公司	用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
US10316369B2 (en)	2014-06-27	2019-06-11	Seminis Vegetable Seeds, Inc.	Methods and assays for male sterile watermelon
WO2016049531A1 (en)	2014-09-26	2016-03-31	Purecircle Usa Inc.	Single nucleotide polymorphism (snp) markers for stevia
EP3005862A1 (en)	2014-10-10	2016-04-13	Seminis Vegetable Seeds, Inc.	Melon plants with improved disease tolerance
WO2016073789A2 (en)	2014-11-05	2016-05-12	Genentech, Inc.	Anti-fgfr2/3 antibodies and methods using same
WO2016077366A1 (en)	2014-11-10	2016-05-19	Genentec, Inc.	Therapeutic and diagnostic methods for il-33-mediated disorders
US9909169B2 (en)	2014-12-17	2018-03-06	Roche Molecular Systems, Inc.	Allele-specific amplification of nucleic acids using blocking oligonucleotides for wild type suppression
CA2982495A1 (en)	2015-04-28	2016-11-03	Monsanto Technology Llc	Methods and compositions for producing brachytic corn plants
WO2016176358A2 (en)	2015-04-30	2016-11-03	Monsanto Technology Llc	Methods for producing canola plants with clubroot resistance and compositions thereof
EP3294906B1 (en)	2015-05-11	2024-07-10	Natera, Inc.	Methods for determining ploidy
AU2016308049B2 (en)	2015-08-18	2022-03-17	Monsanto Technology Llc	Methods for producing cotton plants with enhanced drought tolerance and compositions thereof
US10448595B2 (en)	2015-09-03	2019-10-22	Seminis Vegetable Seeds, Inc.	Downy mildew resistant lettuce plants
WO2017044744A2 (en)	2015-09-10	2017-03-16	Monsanto Technology Llc	Methods for producing corn plants with downy mildew resistance and compositions thereof
MX2018004509A (es)	2015-10-30	2018-08-01	Genentech Inc	Anticuerpos anti-htra1 y metodos de uso de los mismos.
US10694693B2 (en)	2015-12-18	2020-06-30	Monsanto Technology Llc	Methods for producing corn plants with northern leaf blight resistance and compositions thereof
WO2018031874A1 (en)	2016-08-11	2018-02-15	Monsanto Technology Llc	Methods and compositions for producing corn plants with resistance to late wilt
IL264439B2 (en) *	2016-08-17	2024-08-01	Factor Bioscience Inc	A suitable viral preparation containing a synthetic messenger RNA encoding a gene editing protein for use in cancer treatment and a synthetic messenger RNA encoding a gene editing protein for use in therapy
AU2017232187B2 (en)	2016-09-30	2023-11-09	Seminis Vegetable Seeds, Inc.	Xanthomonas resistant brassica oleracea plants
US20190360033A1 (en) *	2016-11-02	2019-11-28	The Medical College Of Wisconsin, Inc.	Methods for assessing risk using mismatch amplification and statistical methods
US11031099B2 (en)	2016-11-09	2021-06-08	Roche Molecular Systems, Inc.	Detection of sequence variants
WO2018118808A1 (en)	2016-12-19	2018-06-28	The Broad Institute, Inc.	Methods of treating autism spectrum disorders
WO2018170436A1 (en)	2017-03-16	2018-09-20	Jacobs Farm Del Cabo	Basil with high tolerance to downy mildew
WO2018200505A1 (en)	2017-04-24	2018-11-01	Genentech, Inc.	Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
US11739389B2 (en)	2017-05-17	2023-08-29	Microbio Pty Ltd	Biomarkers and uses thereof
WO2018237075A1 (en)	2017-06-20	2018-12-27	The Medical College Of Wisconsin, Inc.	ASSESSING THE RISK OF GRAFT COMPLICATION WITH TOTAL ACELLULAR DNA
EP3653729A4 (en)	2017-07-12	2021-06-09	Genecast Co., Ltd.	DNA POLYMERASE WITH INCREASED GENE MUTATIONAL SPECIFICITY AND PCR BUFFER COMPOSITION TO INCREASE THE ACTIVITY OF IT
US11648551B2 (en)	2017-12-12	2023-05-16	Essenlix Corporation	Sample manipulation and assay with rapid temperature change
JP2021506342A (ja)	2017-12-14	2021-02-22	ティーエーアイダイアグノスティックスインコーポレイテッドＴａｉＤｉａｇｎｏｓｔｉｃｓ，Ｉｎｃ．	移植のための移植片適合性の評価
CR20200394A (es)	2018-02-09	2020-11-05	Genentech Inc	Métodos terapéuticos y diagnósticos para enfermedades inflrmatorias mediadas por mostocitos
AU2019251504A1 (en)	2018-04-14	2020-08-13	Natera, Inc.	Methods for cancer detection and monitoring by means of personalized detection of circulating tumor DNA
US11268102B2 (en)	2018-05-16	2022-03-08	University Of Florida Research Foundation, Incorporated	Compositions and methods for identifying and selecting brachytic locus in solanaceae
EP3888021B1 (en)	2018-11-30	2024-02-21	Caris MPI, Inc.	Next-generation molecular profiling
CA3126761C (en)	2019-01-15	2023-01-10	Seminis Vegetable Seeds, Inc.	Green bean plants with improved disease resistance
US11931674B2 (en)	2019-04-04	2024-03-19	Natera, Inc.	Materials and methods for processing blood samples
JPWO2021010326A1 (ko)	2019-07-12	2021-01-21
SG10202008262UA (en)	2019-09-26	2021-04-29	Seminis Vegetable Seeds Inc	Lettuce plants having resistance to nasonovia ribisnigri biotype nr:1
KR20220130108A (ko)	2019-12-02	2022-09-26	캐리스 엠피아이, 아이엔씨.	범-암 백금 반응 예측기
CN115698338A (zh)	2020-03-11	2023-02-03	思进股份有限公司	用妥卡替尼治疗her2突变型癌症的方法
JP2023516497A (ja)	2020-03-13	2023-04-19	メドイミューン・リミテッド	Ｉｌ３３にリスクアレルを有する対象を治療するための治療方法
AU2021204717A1 (en)	2020-07-15	2022-02-03	Seminis Vegetable Seeds, Inc.	Green Bean Plants with Improved Disease Resistance
EP4217400A1 (en)	2020-09-28	2023-08-02	Seagen Inc.	Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody
WO2022108931A2 (en)	2020-11-17	2022-05-27	Seagen Inc.	Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
US20230193310A1 (en)	2021-12-10	2023-06-22	Seminis Vegetabe Seeds, Inc.	Lettuce plants having resistance to downy mildew
WO2023250288A2 (en)	2022-06-21	2023-12-28	Seminis Vegetable Seeds, Inc.	Novel qtls conferring resistance to cucumber mosaic virus
US20240344079A1 (en)	2023-04-14	2024-10-17	Seminis Vegetable Seeds, Inc.	Methods and compositions for peronospora resistance in spinach

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8311018D0 (en) *	1983-04-22	1983-05-25	Amersham Int Plc	Detecting mutations in dna
US4683202A (en) *	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en) *	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CA1284931C (en) *	1986-03-13	1991-06-18	Henry A. Erlich	Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US4851331A (en) *	1986-05-16	1989-07-25	Allied Corporation	Method and kit for polynucleotide assay including primer-dependant DNA polymerase
GB8612087D0 (en) *	1986-05-19	1986-06-25	Ici Plc	Hybridisation probes
GB8709652D0 (en) *	1987-04-23	1987-05-28	Williamson R	Diagnosis of cystic fibrosis
US4994368A (en) *	1987-07-23	1991-02-19	Syntex (U.S.A.) Inc.	Amplification method for polynucleotide assays
CA1323553C (en) *	1987-11-03	1993-10-26	Timothy George Helentjaris	Method and device for improved restriction fragment length polymorphism analysis
AU613989B2 (en) *	1987-11-24	1991-08-15	Gen-Probe Incorporated	Means and method for enhancing nucleic acid hybridization
AU2735988A (en) *	1987-12-21	1989-07-13	Amoco Corporation	Target and background capture methods with amplification for affinity assays
US4999290A (en) *	1988-03-31	1991-03-12	The Board Of Regents, The University Of Texas System	Detection of genomic abnormalities with unique aberrant gene transcripts
WO1989010414A1 (en) *	1988-04-28	1989-11-02	Robert Bruce Wallace	AMPLIFIED SEQUENCE POLYMORPHISMS (ASPs)
AU629845B2 (en) *	1988-08-30	1992-10-15	Abbott Laboratories	Detection and amplification of target nucleic acid sequences
CA1339731C (en) *	1988-10-12	1998-03-17	Charles T. Caskey	Multiplex genomic dna amplification for deletion detection
CA2011818A1 (en) *	1989-03-17	1990-09-17	Fred T. Oakes	Methods for purification, amplification and detection of a nucleic acid
AU5640090A (en) *	1989-03-21	1990-11-05	Collaborative Research Inc.	A dna diagnostic test using an exonuclease activity
CA2013317A1 (en) *	1989-04-17	1990-10-17	Fred T. Oakes	Diagnostic kit, primer composition and their use for replication or detection of nucleic acids
US5137806A (en) *	1989-12-11	1992-08-11	Board Of Regents, The University Of Texas System	Methods and compositions for the detection of sequences in selected DNA molecules
US6004744A (en) *	1991-03-05	1999-12-21	Molecular Tool, Inc.	Method for determining nucleotide identity through extension of immobilized primer

1989
- 1989-03-07 IE IE73989A patent/IE61148B1/en not_active IP Right Cessation
- 1989-03-08 NZ NZ228266A patent/NZ228266A/en unknown
- 1989-03-08 IL IL8954589A patent/IL89545A/en unknown
- 1989-03-08 HU HU891126A patent/HUT52565A/hu unknown
- 1989-03-09 ES ES89302331T patent/ES2039294T5/es not_active Expired - Lifetime
- 1989-03-09 CA CA000593183A patent/CA1323592C/en not_active Expired - Lifetime
- 1989-03-09 EP EP89302331A patent/EP0332435B2/en not_active Expired - Lifetime
- 1989-03-09 YU YU49789A patent/YU49789A/sh unknown
- 1989-03-09 CN CN89102694A patent/CN1034673C/zh not_active Expired - Lifetime
- 1989-03-09 NO NO891012A patent/NO174825B/no not_active IP Right Cessation
- 1989-03-09 FI FI891126A patent/FI891126A/fi not_active Application Discontinuation
- 1989-03-09 AT AT89302331T patent/ATE75262T1/de not_active IP Right Cessation
- 1989-03-09 MY MYPI89000284A patent/MY104957A/en unknown
- 1989-03-09 BG BG087585A patent/BG87585A/bg unknown
- 1989-03-09 DE DE8989302331T patent/DE68901285D1/de not_active Expired - Lifetime
- 1989-03-09 TN TNTNSN89026A patent/TNSN89026A1/fr unknown
- 1989-03-10 PL PL27817689A patent/PL162338B1/pl unknown
- 1989-03-10 BR BR898901136A patent/BR8901136A/pt not_active Application Discontinuation
- 1989-03-10 DK DK198901180A patent/DK175527B1/da not_active IP Right Cessation
- 1989-03-10 KR KR1019890003001A patent/KR970003151B1/ko not_active IP Right Cessation
- 1989-03-10 JP JP1059492A patent/JP2853864B2/ja not_active Expired - Lifetime
- 1989-03-10 PT PT89980A patent/PT89980B/pt not_active IP Right Cessation
- 1989-03-10 ZW ZW33/89A patent/ZW3388A1/xx unknown
- 1989-03-10 AU AU31246/89A patent/AU614584B2/en not_active Expired
1992
- 1992-04-23 GR GR910401845T patent/GR3004442T3/el unknown
1995
- 1995-02-17 US US08/390,939 patent/US5595890A/en not_active Expired - Lifetime
1999
- 1999-10-14 GR GR990402594T patent/GR3031532T3/el unknown

Also Published As

Publication number	Publication date
DK118089D0 (da)	1989-03-10
AU3124689A (en)	1989-09-14
BG87585A (bg)	1993-12-24
NO174825C (ko)	1994-07-13
EP0332435A2 (en)	1989-09-13
GR3004442T3 (ko)	1993-03-31
EP0332435B2 (en)	1999-10-13
NO891012D0 (no)	1989-03-09
IE61148B1 (en)	1994-10-05
CA1323592C (en)	1993-10-26
IL89545A0 (en)	1989-09-10
FI891126A0 (fi)	1989-03-09
HUT52565A (en)	1990-07-28
KR970003151B1 (ko)	1997-03-14
NO891012L (no)	1989-09-11
EP0332435B1 (en)	1992-04-22
BR8901136A (pt)	1989-10-31
DK118089A (da)	1989-09-11
EP0332435A3 (en)	1990-06-27
YU49789A (sh)	1992-09-07
CN1034673C (zh)	1997-04-23
IL89545A (en)	1994-11-11
PL278176A1 (en)	1990-02-05
NZ228266A (en)	1991-05-28
DK175527B1 (da)	2004-11-22
MY104957A (en)	1994-07-30
FI891126A (fi)	1989-09-11
CN1039618A (zh)	1990-02-14
DE68901285D1 (de)	1992-05-27
KR890014750A (ko)	1989-10-25
AU614584B2 (en)	1991-09-05
ES2039294T3 (es)	1993-09-16
PT89980A (pt)	1989-11-10
IE890739L (en)	1989-09-10
US5595890A (en)	1997-01-21
GR3031532T3 (en)	2000-01-31
JP2853864B2 (ja)	1999-02-03
ZW3388A1 (en)	1989-11-22
PT89980B (pt)	1999-12-31
ES2039294T5 (es)	2000-01-16
TNSN89026A1 (fr)	1991-02-04
ATE75262T1 (de)	1992-05-15
PL162338B1 (pl)	1993-10-30
JPH0242999A (ja)	1990-02-13

Publication	Publication Date	Title
NO174825B (no)	1994-04-05	Fremgangsmåte ved påvisning av nukleotidsekvenser, nukleotidsekvens for bruk i denne og diagnostisk sett
DK175469B1 (da)	2004-11-01	Fremgangsmåde til multiplikation og påvisning af nukleinsyresekvenser
JP2726659B2 (ja)	1998-03-11	核酸中に存在する特定のヌクレオチド配列の検出方法及びそのためのキット
US6696277B1 (en)	2004-02-24	Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
JP5386357B2 (ja)	2014-01-15	核酸サイズ検出法
US5496699A (en)	1996-03-05	Detection of allele - specific mutagens
US6200747B1 (en)	2001-03-13	Method and kits for detection of fragile X specific, GC-rich DNA sequences
JP5637850B2 (ja)	2014-12-10	標的核酸配列の増幅方法、それを用いた変異の検出方法、および、それに用いる試薬
US20040166506A1 (en)	2004-08-26	Methods and compositions for genotyping
JP5917144B2 (ja)	2016-05-11	疾患関連遺伝子の多型検出用プローブおよびその用途
JP2002510962A (ja)	2002-04-09	男性不妊ｙ欠失検出器具
CN106591442B (zh)	2020-05-05	用于y染色体微缺失检测的引物组合及试剂盒
US9284603B2 (en)	2016-03-15	Target sequence amplification method, polymorphism detection method, and reagents for use in the methods
JPH11507222A (ja)	1999-06-29	マルチプレックスプライマー結合による男性不妊ｙ染色体欠失検出
JPWO2011077990A1 (ja)	2013-05-02	ｃ−ｋｉｔ遺伝子の多型検出用プローブおよびその用途
RU2099426C1 (ru)	1997-12-20	Способ определения последовательности нуклеотидов
JP5635496B2 (ja)	2014-12-03	Ｅｇｆｒ遺伝子多型検出用プローブおよびその用途
JP5568935B2 (ja)	2014-08-13	標的塩基配列の識別方法

Legal Events

Date	Code	Title	Description
2009-03-16	MK1K	Patent expired